Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on September 6, 2005

Circulation. 2005
Published online before print September 6, 2005, doi: 10.1161/CIRCULATIONAHA.104.525550
A more recent version of this article appeared on September 13, 2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
112/11/1636    most recent
CIRCULATIONAHA.104.525550v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iwai, M.
Right arrow Articles by Horiuchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwai, M.
Right arrow Articles by Horiuchi, M.
Related Collections
Right arrow ACE/Angiotension receptors

Submitted on November 29, 2004
Revised on April 21, 2005
Accepted on June 13, 2005

Deletion of Angiotensin II Type 2 Receptor Exaggerated Atherosclerosis in Apolipoprotein E-Null Mice

Masaru Iwai MD, PhD, Rui Chen MD, PhD, Zhen Li MD, PhD, Tetsuya Shiuchi PhD, Jun Suzuki MD, PhD, Ayumi Ide BS, Masahiro Tsuda MD, PhD, Midori Okumura MD, Li-Juan Min MD, Masaki Mogi MD, PhD, and Masatsugu Horiuchi MD, PhD*

From the Department of Molecular and Cellular Biology, Division of Medical Biochemistry and Cardiovascular Biology, Ehime University School of Medicine, Shitsukawa, Tohon, Ehime, Japan.

* To whom correspondence should be addressed. E-mail: horiuchi{at}m.ehime-u.ac.jp.

Background--The role of angiotensin II (Ang II) type 2 (AT2) receptor in atherosclerosis was explored with the use of AT2 receptor/apolipoprotein E (ApoE)-double-knockout (AT2/ApoE-DKO) mice, with a focus on oxidative stress.

Methods and Results--After treatment with a high-cholesterol diet (1.25% cholesterol) for 10 weeks, ApoE-knockout (KO) mice developed atherosclerotic lesions in the aorta. In AT2/ApoE-DKO mice receiving a high-cholesterol diet, the atherosclerotic changes were further exaggerated, without significant changes in plasma cholesterol level and blood pressure. In the atherosclerotic lesion, an increase in superoxide production, NADPH oxidase activity, and expression of p47phox was observed. These changes were also greater in AT2/ApoE-DKO mice. An Ang II type 1 (AT1) receptor blocker, valsartan, inhibited atherosclerotic lesion formation, superoxide production, NADPH oxidase activity, and p47phox expression; these inhibitory effects were significantly weaker in AT2/ApoE-KO mice. We further examined the signaling mechanism of the AT2 receptor-mediated antioxidative effect in cultured fetal vascular smooth muscle cells. NADPH oxidase activity and phosphorylation and translocation of p47phox induced by Ang II were inhibited by valsartan but enhanced by an AT2 receptor blocker, PD123319.

Conclusions--These results suggest that AT2 receptor stimulation attenuates atherosclerosis through inhibition of oxidative stress and that the antiatherosclerotic effect of valsartan could be at least partly due to AT2 receptor stimulation by unbound Ang II.


Key words: angiotensin • atherosclerosis • receptors • oxidative stress




This article has been cited by other articles:


Home page
HypertensionHome page
T. Fujita, M. Mogi, L.-J. Min, J. Iwanami, K. Tsukuda, A. Sakata, H. Okayama, M. Iwai, C. Nahmias, J. Higaki, et al.
Attenuation of Cuff-Induced Neointimal Formation by Overexpression of Angiotensin II Type 2 Receptor-Interacting Protein 1
Hypertension, April 1, 2009; 53(4): 688 - 693.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L.-J. Min, M. Mogi, J. Iwanami, J.-M. Li, A. Sakata, T. Fujita, K. Tsukuda, M. Iwai, and M. Horiuchi
Angiotensin II Type 2 Receptor Deletion Enhances Vascular Senescence by Methyl Methanesulfonate Sensitive 2 Inhibition
Hypertension, May 1, 2008; 51(5): 1339 - 1344.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
T. Hashimoto, M. Kihara, N. Imai, S.-i. Yoshida, H. Shimoyamada, H. Yasuzaki, J. Ishida, Y. Toya, Y. Kiuchi, N. Hirawa, et al.
Requirement of Apelin-Apelin Receptor System for Oxidative Stress-Linked Atherosclerosis
Am. J. Pathol., November 1, 2007; 171(5): 1705 - 1712.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Yusof, K. Kamada, F. Spencer Gaskin, and R. J. Korthuis
Angiotensin II mediates postischemic leukocyte-endothelial interactions: role of calcitonin gene-related peptide
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3032 - H3037.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Oelze, A. Warnholtz, J. Faulhaber, P. Wenzel, A. L. Kleschyov, M. Coldewey, U. Hink, O. Pongs, I. Fleming, S. Wassmann, et al.
NADPH Oxidase Accounts for Enhanced Superoxide Production and Impaired Endothelium-Dependent Smooth Muscle Relaxation in BK{beta}1-/- Mice
Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1753 - 1759.
[Abstract] [Full Text] [PDF]